Receptor, Fibroblast Growth Factor, Type 2
"Receptor, Fibroblast Growth Factor, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fibroblast growth factor receptor that is found in two isoforms. One receptor isoform is found in the MESENCHYME and is activated by FIBROBLAST GROWTH FACTOR 2. A second isoform of fibroblast growth factor receptor 2 is found mainly in EPITHELIAL CELLS and is activated by FIBROBLAST GROWTH FACTOR 7 and FIBROBLAST GROWTH FACTOR 10. Mutation of the gene for fibroblast growth factor receptor 2 can result in craniosynostotic syndromes (e.g., APERT SYNDROME; and CROUZON SYNDROME).
MeSH Number(s)
D08.811.913.696.620.682.725.400.178
D12.776.543.750.060.441
D12.776.543.750.750.400.370.750
Concept/Terms
Receptor, Fibroblast Growth Factor, Type 2- Receptor, Fibroblast Growth Factor, Type 2
- BEK Fibroblast Growth Factor Receptor
- BEK Fibroblast Growth Factor Receptor Kinase
- BEK Protein Tyrosine Kinase
- FGFR2 Protein
- Fibroblast Growth Factor Receptor 2
- Fibroblast Growth Factor Receptors 2
- Bek Fgf Receptor Kinase
- Bek-Related Fibroblast Growth Factor-Receptor-1
- Bek Related Fibroblast Growth Factor Receptor 1
Below are MeSH descriptors whose meaning is more general than "Receptor, Fibroblast Growth Factor, Type 2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, Fibroblast Growth Factor, Type 2 [D08.811.913.696.620.682.725.400.178]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.060]
- Receptor, Fibroblast Growth Factor, Type 2 [D12.776.543.750.060.441]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Fibroblast Growth Factor [D12.776.543.750.750.400.370]
- Receptor, Fibroblast Growth Factor, Type 2 [D12.776.543.750.750.400.370.750]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Fibroblast Growth Factor, Type 2".
This graph shows the total number of publications written about "Receptor, Fibroblast Growth Factor, Type 2" by people in Harvard Catalyst Profiles by year, and whether "Receptor, Fibroblast Growth Factor, Type 2" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 3 | 4 |
| 2008 | 3 | 1 | 4 |
| 2009 | 3 | 3 | 6 |
| 2010 | 1 | 4 | 5 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 4 | 6 |
| 2013 | 3 | 1 | 4 |
| 2014 | 5 | 2 | 7 |
| 2015 | 3 | 2 | 5 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 3 | 4 |
| 2018 | 3 | 0 | 3 |
| 2019 | 4 | 4 | 8 |
| 2020 | 4 | 5 | 9 |
| 2021 | 3 | 1 | 4 |
Below are the most recent publications written about "Receptor, Fibroblast Growth Factor, Type 2" by people in Profiles.
-
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology. 2021 09; 74(3):1429-1444.
-
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815.
-
Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. Angew Chem Int Ed Engl. 2021 07 12; 60(29):15905-15911.
-
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 10; 11(10):2488-2505.
-
Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. Eur J Med Chem. 2021 Aug 05; 220:113499.
-
Fibroblast Growth Factor Receptor Inhibitors and Nonuremic Calciphylaxis. JAMA Dermatol. 2021 01 01; 157(1):119-121.
-
Epigenetic Alterations in Keratinocyte Carcinoma. J Invest Dermatol. 2021 05; 141(5):1207-1218.
-
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clin Cancer Res. 2020 11 15; 26(22):5974-5989.
-
A sequential methodology for the rapid identification and characterization of breast cancer-associated functional SNPs. Nat Commun. 2020 07 03; 11(1):3340.
-
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020 Oct; 16(30):2375-2384.